Atlas Brown Inc. Acquires 518 Shares of Bristol-Myers Squibb (NYSE:BMY)

Atlas Brown Inc. raised its holdings in Bristol-Myers Squibb (NYSE:BMY) by 3.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,559 shares of the biopharmaceutical company’s stock after acquiring an additional 518 shares during the period. Atlas Brown Inc.’s holdings in Bristol-Myers Squibb were worth $937,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of BMY. Sage Capital Advisors llc lifted its stake in Bristol-Myers Squibb by 1.0% in the 4th quarter. Sage Capital Advisors llc now owns 57,039 shares of the biopharmaceutical company’s stock valued at $3,226,000 after purchasing an additional 567 shares during the last quarter. LVM Capital Management Ltd. MI increased its holdings in shares of Bristol-Myers Squibb by 3.7% during the fourth quarter. LVM Capital Management Ltd. MI now owns 14,054 shares of the biopharmaceutical company’s stock worth $795,000 after buying an additional 504 shares in the last quarter. Franklin Street Advisors Inc. NC lifted its stake in shares of Bristol-Myers Squibb by 7,223.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 347,402 shares of the biopharmaceutical company’s stock valued at $19,649,000 after acquiring an additional 342,658 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Bristol-Myers Squibb by 1.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 354,161 shares of the biopharmaceutical company’s stock valued at $18,324,000 after acquiring an additional 3,827 shares in the last quarter. Finally, Partnership Wealth Management LLC raised its position in Bristol-Myers Squibb by 6.3% in the fourth quarter. Partnership Wealth Management LLC now owns 27,867 shares of the biopharmaceutical company’s stock valued at $1,576,000 after purchasing an additional 1,658 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of a number of research reports. Jefferies Financial Group raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and boosted their target price for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Morgan Stanley increased their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Finally, UBS Group lifted their price objective on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 9th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $56.27.

Bristol-Myers Squibb Stock Down 1.5 %

Shares of BMY traded down $0.87 during trading hours on Friday, reaching $55.94. The stock had a trading volume of 6,584,923 shares, compared to its average volume of 9,487,040. The firm has a 50-day simple moving average of $57.41 and a 200 day simple moving average of $51.34. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The company has a market capitalization of $113.46 billion, a price-to-earnings ratio of -15.58, a P/E/G ratio of 15.20 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. During the same period last year, the company earned $2.00 earnings per share. The business’s revenue was up 8.4% on a year-over-year basis. Equities research analysts predict that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be issued a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, January 3rd. This represents a $2.48 annualized dividend and a yield of 4.43%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio is -69.08%.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,830 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.